Inhibitors of HCV replication of formula I
including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R′ are, each independently, —CR
1
R
2
R
3
, aryl, heteroaryl or heteroC
4-6
cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl.
The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
Inhibitors of HCV replication of formula I
including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R′ are, each independently, —CR
1
R
2
R
3
, aryl, heteroaryl or heteroC
4-6
cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl.
The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
Inhibitors of HCV replication of formula I
including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R′ are, each independently, —CR
1
R
2
R
3
, aryl, heteroaryl or heteroC
4-6
cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl.
The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.